Hygieia, a virtual insulin management startup, has raised USD 22 million in its extended Series B funding round led by Firstime Ventures, with additional investment from two strategic partners.
The funds will be used to expand product reach to insulin users by entering new markets across the US. The company is currently building a network of diabetes care centers through a partnership program for providers treating type 2 diabetes patients. The d-Nav Clinical Partnership Program is available in Michigan, Texas, Arizona, and North Carolina.
Hygieia develops d-Nav, an FDA-cleared technology that autonomously adjusts insulin dose recommendations for insulin users. The technology aims to improve A1C levels without increasing the risk of hypoglycemia. The d-Nav Insulin Management Program is covered by Medicare and several other health plans.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.